查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387497

多形性胶质母细胞瘤 (GBMF) 市场报告：2030 年趋势、预测和竞争分析

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

多形性胶质母细胞瘤（GBMF）的趋势和预测

预计到 2030 年，全球多形性胶质母细胞瘤 (GBMF) 市场预计将达到 12 亿美元，2024 年至 2030 年年复合成长率为 8.2%。市场的主要驱动因素是研发费用不断上升、多形性胶质母细胞瘤（GBMF）盛行率不断上升、有利的法规环境以及脑肿瘤盛行率不断上升以及强大的产品平臺。全球多形性胶质母细胞瘤 (GBMF) 市场的未来前景看好，医院、诊所和门诊手术中心市场存在商机。

多形性胶质母细胞瘤 (GBMF) 市场洞察

Lucintel 预测，由于放射线治疗的效率和对復发性脑肿瘤病例的强大支持，以及放射技术的进步和生存率的提高，放射治疗在预测期内将继续成为最大的细分市场。

由于政府对医疗保健产业发展的支持、对罕见疾病的广泛认识、优质医疗设施的便利性以及有利的报销政策，北美在预测期内可能仍是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球多形性胶质母细胞瘤 (GBMF) 市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球多形性胶质母细胞瘤 (GBMF) 市场趋势 (2018-2023) 和预测 (2024-2030)
  • 按治疗分類的全球多形性胶质母细胞瘤 (GBMF) 市场
    • 外科手术
    • 放射线治疗
    • 化疗
    • 标靶治疗
    • 肿瘤治疗电场治疗
    • 免疫疗法
  • 按药物分類的全球多形性胶质母细胞瘤 (GBMF) 市场
    • Temozolomide
    • Bevacizumab
    • Lomustine
    • Carmustine晶圆
    • 其他的
  • 以最终用途分類的全球多形性胶质母细胞瘤 (GBMF) 市场
    • 医院
    • 诊所
    • 门诊手术中心

第4章2018-2030年分地区市场趋势及预测分析

  • 全球多形性胶质母细胞瘤 (GBMF) 市场（按地区）
  • 北美多形性胶质母细胞瘤（GBMF）市场
  • 欧洲多形性胶质母细胞瘤（GBMF）市场
  • 亚太地区多形性胶质母细胞瘤（GBMF）市场
  • 其他地区多形性胶质母细胞瘤（GBMF）市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球多形性胶质母细胞瘤 (GBMF) 治疗市场成长机会
    • 全球多形性胶质母细胞瘤 (GBMF) 药物市场成长机会
    • 全球多形性胶质母细胞瘤 (GBMF) 市场成长机会（以最终用途）
    • 全球多形性胶质母细胞瘤 (GBMF) 市场成长机会（按地区）
  • 全球多形性胶质母细胞瘤（GBMF）市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球多形性胶质母细胞瘤 (GBMF) 市场容量扩张
    • 全球多形性胶质母细胞瘤 (GBMF) 市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology
简介目录

Glioblastoma Multiforme Trends and Forecast

The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets. The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030 with a CAGR of 8.2% from 2024 to 2030. The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

A more than 150-page report is developed to help in your business decisions.

Glioblastoma Multiforme by Segment

The study includes a forecast for the global glioblastoma multiforme by treatment, drug, end use, and region.

Glioblastoma Multiforme Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Tumor Treating Field Therapy
  • Immunotherapy

Glioblastoma Multiforme Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Temozolomide
  • Bevacizumab
  • Lomustine
  • Carmustine Wafers
  • Others

Glioblastoma Multiforme Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Glioblastoma Multiforme Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Glioblastoma Multiforme Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glioblastoma multiforme companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glioblastoma multiforme companies profiled in this report include-

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology

Glioblastoma Multiforme Market Insights

Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Features of the Global Glioblastoma Multiforme Market

Market Size Estimates: Glioblastoma multiforme market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glioblastoma multiforme market size by treatment, drug, end use, and region in terms of value ($B).

Regional Analysis: Glioblastoma multiforme market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatment, drug, end use, and regions for the glioblastoma multiforme market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glioblastoma multiforme market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glioblastoma multiforme market size?

Answer: The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030.

Q2. What is the growth forecast for glioblastoma multiforme market?

Answer: The global glioblastoma multiforme market is expected to grow with a CAGR of 8.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glioblastoma multiforme market?

Answer: The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

Q4. What are the major segments for glioblastoma multiforme market?

Answer: The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets.

Q5. Who are the key glioblastoma multiforme market companies?

Answer: Some of the key glioblastoma multiforme companies are as follows:

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology

Q6. Which glioblastoma multiforme market segment will be the largest in future?

Answer: Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

Q7. In glioblastoma multiforme market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the glioblastoma multiforme market by treatment (surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy), drug (temozolomide, bevacizumab, lomustine, carmustine wafers, and others), end use (hospitals, clinics, and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glioblastoma Multiforme Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Glioblastoma Multiforme Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Glioblastoma Multiforme Market by Treatment
    • 3.3.1: Surgery
    • 3.3.2: Radiation Therapy
    • 3.3.3: Chemotherapy
    • 3.3.4: Targeted Therapy
    • 3.3.5: Tumor Treating Field Therapy
    • 3.3.6: Immunotherapy
  • 3.4: Global Glioblastoma Multiforme Market by Drug
    • 3.4.1: Temozolomide
    • 3.4.2: Bevacizumab
    • 3.4.3: Lomustine
    • 3.4.4: Carmustine Wafers
    • 3.4.5: Others
  • 3.5: Global Glioblastoma Multiforme Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Ambulatory Surgical Centers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Glioblastoma Multiforme Market by Region
  • 4.2: North American Glioblastoma Multiforme Market
    • 4.2.2: North American Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.3: European Glioblastoma Multiforme Market
    • 4.3.1: European Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.3.2: European Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.4: APAC Glioblastoma Multiforme Market
    • 4.4.1: APAC Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.4.2: APAC Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.5: ROW Glioblastoma Multiforme Market
    • 4.5.1: ROW Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.5.2: ROW Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Glioblastoma Multiforme Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Glioblastoma Multiforme Market by Drug
    • 6.1.3: Growth Opportunities for the Global Glioblastoma Multiforme Market by End Use
    • 6.1.4: Growth Opportunities for the Global Glioblastoma Multiforme Market by Region
  • 6.2: Emerging Trends in the Global Glioblastoma Multiforme Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Glioblastoma Multiforme Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glioblastoma Multiforme Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Merck & Co
  • 7.2: Amgen
  • 7.3: F. Hoffmann-La Roche
  • 7.4: Pfizer
  • 7.5: Teva Pharmaceutical Industries
  • 7.6: Sun Pharmaceutical Industries
  • 7.7: Pharmaceuticals
  • 7.8: Amneal Pharmaceuticals
  • 7.9: Karyopharm Therapeutics
  • 7.10: Sumitomo Dainippon Pharma Oncology